A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

Table 2 Participants performance during the 12 weeks of training

	All	Walk	Strength-walk
Adherence (%)	67 (58–75)	61 (56–72)	69 (63–79)
Total walked distance (Km)	122 (84–146)	105^c (73–139)	136^c (121–155)
Total energy expenditure (KJ/Kg)^a	298.18 (205.31-356.84)	248.84 (173.00-329.84)	344.67 (306.65-392.82)
Walked distance/session (m)	5040 (4380–5500)	4740^d (3535–5390)	5330^d (4980–5700)
Energy expenditure per session (KJ/Kg)^a	12.32 (10.10-14.28)	11.23 (8.01-13.77)	13.51 (12.09-15.25)
HR_mean (% of HR_max)^b	66 (62–75)	66 (58–73)	70 (63–86)

Values as expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
^aCalculation was based on the U shape relationship between walking metabolic cost and speed [43]
^bThe median HR_mean value was calculated for each participant through all her/his walking sessions, to derive the median HR_mean value of all participants
^cWalk vs. strength-walk group, p = 0.029 (Mann–Whitney test)
^dWalk vs. strength-walk group, p = 0.027 (Mann–Whitney test)
No significant differences were observed between the two training groups for adherence, total and per session energy expenditure, and HR_mean
HR heart rate

ISSN: 1471-2334